The secondary endpoints are event-free survival, complete pathological response, downstaging, disease-free survival (DFS), OS, MPR in patients with or without detectable EGFR mutations in plasma circulating tumor DNA at screening, disease-related symptoms, and health-related quality of life, as well as safety and tolerability. This evidence concerns the gene EGFR and neoplasm.